Literatura ACTA MEDICINAE 10 11/2018 Onkologie Hematoonkologie

Literatura 3 Imunoterapie nemalobuněčných karcinomů plic současný stav a budoucnost prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 3 Léčba karcinomu plic aktuálně a výhledy MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 4 Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017) MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha 4 Studie APHINITY: Adjuvantní léčba zachraňuje životy prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň 4 Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6 MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno 4 Pertuzumab v neoadjuvantní léčbě karcinomu prsu MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno 4 Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny? prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň 5 Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem kazuistika MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha 5 Levá a pravá význam lokalizace primárního nádoru u kolorektálního karcinomu MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha 5 Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno 5 Teysuno v léčbě metastatického karcinomu žaludku MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno 5 Ramucirumab cílený zásah jaterních metastáz karcinomu gastroezofageální junkce kazuistika MUDr. Sabina Svobodová MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně MUDr. Adam Peštál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně 6 Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem? MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 6 Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem kazuistika MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha 6 Pacient s mnohočetným recidivujícím bazocelulárním karcinomem kazuistika MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec 6 Lenvatinib nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc 6 Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy? MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha 7 Hodgkinův lymfom u starších nemocných MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha 8 Můžeme upravit intenzitu úvodní léčby u Hodgkinova lymfomu podle výsledku průběžného PET? doc. MUDr. Vít Procházka, Ph.D. MUDr. Marie Lukášová Hemato-onkologická klinika Fakultní nemocnice Olomouc MUDr. Lenka Henzlová, Ph.D. Klinika nukleární medicíny Fakultní nemocnice Olomouc prof. MUDr. Tomáš Papajík, CSc. Hemato-onkologická klinika Fakultní nemocnice Olomouc

8 Primární lymfom centrální nervové soustavy kam kráčíš? MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha 8 Úspěšná léčba obinutuzumabem s chlorambucilem u staršího pacienta s masivní lymfadenopatií kazuistika MUDr. Martin Špaček, Ph.D. I. interní klinika klinika hematologie 1. LF UK a VFN, Praha 9 Úspěšná léčba venetoklaxem u pacientky s abruptivním relapsem předléčené relabující/refrakterní chronické lymfocytární leukemie po selhání terapie idelalisibem a ibrutinibem kazuistika MUDr. Peter Turcsányi, Ph.D. MUDr. Renata Urbanová, Ph.D. prof. MUDr. Tomáš Papajík CSc. Hemato-onkologická klinika FN Olomouc 9 Aktuální léčba relabované a refrakterní chronické lymfocytární leukemie kazuistika MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové 9 Management lymfomů v těhotenství MUDr. Jan Kořen I. interní klinika klinika hematologie, 1. LF UK a VFN, Praha 9 Příznivý vliv dasatinibu na kompenzaci diabetu u pacienta s chronickou myeloidní leukemií kazuistika MUDr. Petra Bělohlávková, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové 10 Nová doporučení pro léčbu chronické lymfocytární leukemie a ibrutinib MUDr. Jakub Trizuljak prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, LF a FN Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno

Imunoterapie nemalobuněčných karcinomů plic současný stav a budoucnost prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Brahmer, J. Reckamp, K. L. Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015, 373, s. 123 135. 2 Borghaei, H. Paz-Ares, L. Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 201, 373, s. 1627 1639. 3 Herbst, R. S. Baas, P. Kim, D. W., et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387, s. 1540 1550. 4 Rittmeyer, A. Barlesi, F. Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389, s. 255 265. 5 Kim, J. M. Chen, D. S.: Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). An Oncol, 2016, 27, s. 1492 1504. 6 Chen, D. S. Mellamn, I.: Elements of cancer imunity and the cancerimmune set point. Nature, 2017, 541, s. 321 330. 7 Hegde, P. S. Karanikas, V. Evers, S.: The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res, 2016, 22, s. 1865 1874. 8 Gandhi, L. Rodríguez-Abreu, D. Gadgeel S, et al.; Keynote-189 investigators: Pembrolizumab plus chemotherapy in metastatic nonsmall-cell lung cancer. N Engl J Med, 2018, 378, s. 2078 2092, doi: 10.1056/NEJMoa1801005. 9 Socinsky, M. A. Jotte, R. M. Frederico Cappuzo, M. D., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s. 2288 2301. 10 Hellmann, M. D. Ciuleanu, T-E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s. 2093 2104. 11 Melosky B.: Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Mini review article. Front Oncol, 20. 3. 2017, https://doi.org/10.3389/fonc.2017.00038. 12 Reck, M. Rodrígues-Abreu, D. Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375, s. 1823 1833 13 Lopes, G. Wu, Y. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol, 2018, 36, suppl., abstrakt LBA4. 14 Paz-Ares, L. Luft, A. Tafreshi, A., et al.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol, suppl., 2018, http:// ascopubs.org/doi/abs/10.1200/jco.2018.36.15_suppl.105. 15 Carbone, D. P. Reck, M. Paz-Ares, L., et al.: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med, 2017, 376, s. 2415 2426. 16 Borghaei, H. Paz-Ares, L. Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373, s. 1627, doi: 10.1056/NEJMoa1507643; J Clin Oncol, suppl., 2018. Léčba karcinomu plic aktuálně a výhledy MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 1 Scagliotti, G. V., et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26, s. 3543 3551. 2 Yang, J. C., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943, přednáška. Prezentováno na 16 th World Conference on Lung Cancer, 6. 9. 9. 2015, Denver, CO. 3 Mitsudomi, T., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406, přednáška. Prezentováno na 16 th World Conference on Lung Cancer, 6. 9. 9. 2015, Denver, CO. 4 Mok, T. S. Wu, Y. L. Ahn, M. J., et al.: Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376, s. 629 640. 5 Soria, J. C. Ohe, Y. Vansteenkiste, J., et al.: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378, s. 113 125. 6 Vansteenkiste, J. Reungwetwattana, T. Nakagawa, K., et al.: CNS response to osimertinib vs standard-of-care EGFR-TKI as firstline treatment in patients with EGFRm advanced NSCLC: FLAURA. Prezentováno na European Society of Medical Oncology Asia Congress, 17. 19. 11. 2017, Singapur, abstrakt LBA5. 7 Thatcher, N. Hirsch, F. R. Luft, A. V., et al.: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncology, 2015, 16, s. 763 774. 8 Soria, J. C. Tan, D. S. Chiari, R., et al.: First-line ceritinib versus platinum based chemotherapy in advanced ALK-rearranged nonsmall cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, Epub 24. 1. 2017. 9 Shaw, A. T. Kim, T. M. Crinò,L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet, 2017, 18, s. 874 886. 10 Gettinger, S. N. Bazhenova, L. A. Langer, C. J., et al.: Activity and safety of brigatinib in ALK-rearranged non-small cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol, 2016, 17, s. 1683 1696. 11 Camidge, D. Tiseo, M. Ahn, M., et al.: Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial. Prezentováno na 17 th World Conference on Lung Cancer, prosinec 2016, Vídeň, Rakousko. 12 Solomon, B., et al.: Phase 2 study of lorlatinib in patients with advanced ALK+ /ROS1+ non-small-cell lung cancer. Prezentováno na International Association for the Study of Lung Cancer (IASLC) 18 th World Conference on Lung Cancer, 16. 10. 2017, abstrakt #OA 05.06. 13 Novello, S. Mazières, J. Oh, I.-J., et al.: Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)- positive non-small-cell lung cancer: results from the phase III ALUR study. An Oncol, mdy121, https://doi.org/10.1093/annonc/mdy121. 14 Solange, P. Ross Camidge, D. Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017, 377, s. 829 838. 15 Camidge, D. R., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt 9043. 16 Shaw, A. T., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371, s. 1963 1971. 17 Ahn, M.-J. Cho, B. C. Siena, S., et al.: Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). Prezentováno na IASLC 18 th World Conference on Lung Cancer, 15. 18. 10. 2017, Jokohama, Japonsko, abstrakt 8564. 18 Drilon, A. De Braud, F. G. Siena S, et al.: Entrectinib, an oral pan- Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements. Prezentováno na AACR Annual Meeting, 16. 20. 4. 2016, New Orleans, Louisiana, abstrakt CT007. 19 Sandler, A., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEJM, 2006, 355, s. 2542 2550. 20 Reck, M. Kaiser, R. Mellemgaard, A., et al.: LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME- Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 2014, 15, s. 143 155, doi: 10.1016/S1470-2045(13)70586-2, Epub 9. 1. 2014. 21 Garon, E. B. Ciuleanu, T-E. Arrieta, O., et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014, 384, s. 665 673. 22 Seto, T. Kato, T. Nishio, M., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO 25567): an open-label,randomised, multicentre, phase 2 study. Lancet Oncol, 2014, 15, s. 1236 1244. 23 Brahmer, J. R. Rodriguez-Abreu, D. Robinson, A. G., et al.: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE-024. 2017 ASCO Annual Meeting. J Clin Oncol, 2017, 35, suppl., abstrakt 9000. 24 Spigel, D. R., et al.: A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol, 2015, 33, suppl., abstrakt 8009. 25 Paz-Ares, L. Horn, L. Borghaei, H., et al.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-sq) non-small cell lung cancer (NSCLC). J Clin Oncol, 2015, 33, suppl., abstrakt LBA109. 26 Horn, L. Spigel, D. R. Vokes, E. E., et al.: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057). J Clin Oncol, 2017, 35, s. 3924 3933. 27 Herbst, R. S. Kim, D.-W. Felip, E., et al.: KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy. Prezentováno na ESMO Asia 2015 Congress, Singapur, 18. 21. 12. 2015, LBA3 PR. 28 Rittmeyer, A. Barlesi, F. Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389, s. 255 265. 29 Papadimitrakopoulou, V. Gadgeel, S. M. Borghaei, H., et al.: Firstline carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. J Clin Oncol, 2017, 35, suppl., s. 9094 9094, DOI: 10.1200/JCO.2017.35.15_suppl.9094. 30 Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, 16. 4. 2018. 31 Reck, M., et al.: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IM- POWER150). An Oncol, 2017, 28, suppl. 11, 1. 12. 2017, mdx760.002. 32 Socinski, M. A., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s. 2288 2301. 33 Borghaei, et al.: Nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy in chemo-naive patients with advanced nonsmall cell lung cancer and < 1 % tumor PD-L1 expression: results from CheckMate 227. Prezentováno na ASCO 2018 Meeting (přednáška). 34 Jotte, R. M. Cappuzzo, F. Vynnychenko, I., et al.: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt LBA9000. 35 Scott, J. A. Bendell, J. C. Tailor, M. H., et al.: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol, 2015, 33, suppl., abstrakt 7503). 36 Hellmann, M. D. Ciuleanu, T. E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s. 2093 2104. 37 Scott, J. A. Villegas, A. Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, November 16, 2017. N Engl J Med, 2017, 377, s. 1919 1929. 38 Antonia, S. J. Villegas, A. Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [article and supplementary appendix]. N Engl J Med, 2017, 377, s. 1919 1929. 39 Hellmann, M. D. Callahan, M. K. Awad, M. M., et al.: Tumor mutation burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small cell lung cancer. Cancer Cell, 2018, 33, s. 853 861. 40 Camidge, D. R., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. NCT02075840, ASCO 2018. J Clin Oncol, 2018, 36, suppl., abstrakt 9043. 41 Brahmer, J., et al.: Updated analysis of KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD- L1 TPS 50%. Prezentováno na WCLC 2017, abstrakt OA17.06. J Thor Oncol, 2017, 12, suppl. 2, s. S1793 S1794, https://doi.org/10.1016/j. jtho.2017.09.431. 42 Lopes, G. Wu Y.-L. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Prezentováno na ASCO 2018. J Clin Oncol, 2018, 36, suppl., abstrakt LBA4. 43 Paz-Ares, L. G. Luft, A. Tafreshi, A., et al.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Prezentováno na ASCO 2018. J Clin Oncol, 2018, 36, suppl., abstrakt 105. 44 Socinski, M. A. Jotte, R. M. Cappuzzo, F., et al.: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt 9002.

Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017) MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha 1 Skřičková, J. Kolek, V., et al.: Základy moderní pneumoonkologie. Maxdrof Jesenius, 2017, s. 168. 2 Rangachari, D. Yamaguchi, N. Van der Laan, P. A., et al.: Brain metastases in patients with EGFR-mutated or ALK-rearranged nonsmall-cell lung cancers. Lung Cancer, 2015, s. 88:108 111. 3 Peters, S. Camidge, D. R. Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017, 377, s. 829 838. 4 SPC Alectinib. 5 Camidge, D. R. Peters, S. Mok, T., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. ASCO 2018. J Clin Oncol, 2018, 36, suppl., abstrakt 9043. 6 Novello, S. Barlesi, F., et. al.: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Publikováno 2016. Ann Oncol, 2016, 27, suppl. 5, v1 v27. 7 www.sukl.cz Studie APHINITY: Adjuvantní léčba zachraňuje životy prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň 1 Minckwitz, G. Procter, M. Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med, 2017, 377, s. 122 131, doi: 10.1056/NEJMoa1703643, Epub 5. 6. 2017. Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6 MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno 1 Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Eng J Med, 2012, 366, s. 520 529. 2 Fasching, P. A., et al.: Breast cancer treatment with everolimus and exemestane for ER+ women-results of the 2 nd interim amalysis of the non-interventional trial brawo. An Oncol, 2014, 25, suppl. 4, mdu438. 6. 3 Finn, R. S., et al.: Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2 advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 2014, 74, suppl., CT101. 4 Finn, R. S., et al.: Palbociclib and letrozole in advanced breast cancer. New Eng J Med, 2016, 375, s. 1925 1936. 5 Cristofanilli, M., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s. 425 439. 6 Finn, R. S., et al.: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontone treatment of ER+/HER2 advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol, 2017, 35, suppl. 1001, DOI: 10.1200/ JCO.2017.35.15_suppl.1001. 7 Hortobagyi, G. N., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New Eng J Med, 2016, 375, s. 1738 1748. 8 Hortobagyi, G. N., et al.: Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptorpositive (HR+), HER2-negative (HER2 ), advanced breast cancer (ABC). Ann Oncol, 2018, 29, s. 1541 1547, doi: 10.1093/annonc/mdy155. 9 Slamon, D. J., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, JCO2018789909, doi: 10.1200/JCO.2018.78.9909. 10 Didkler, M. N., et al.: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2 breast cancer, after chemotherapy for advanced disease. J Clin Oncol, 2016, 34, suppl. 510, DOI: 10.1200/ JCO.2016.34.15_suppl.510. 11 Goetz, M. P., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s. 3638 3646, doi: 10.1200/JCO.2017.75.6155, Epub 2. 10. 2017. 12 Sledge, J. R. George, W., et al.: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 35, s. 2875 2884. Pertuzumab v neoadjuvantní léčbě karcinomu prsu MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno 1 Teshome, M. Hunt, K. K.: Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am, 2014, 23, s. 505 523. 2 Vyzula, R., et al.: Modrá kniha ČOS ČLS JEP. Aktualizace: 24. Brno, Masarykův onkologický ústav. 3 Perez, E. A. Romond, E. H. Suman, V. J., et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014, 32, s. 3744 3752. 4 Gianni, L. Eiermann, W. Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer: a randomised controlled superiority trial with a parallel HER2-negative cohort (the NOAH trial). Lancet, 2010, 375, s. 377 384. 5 Gianni, L. Eiermann, W. Semiglazov, V., et al.: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol, 2014, 15, s. 640 647. 6 Fendly, B. M. Winget, M. Hudziak, R. M., et al.: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res, 1990, 50, s. 1550 1558. 7 Gianni, L. Pienkowski, T. Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s. 25 32. 8 Gianni, L. Pienkowski, T. Im, Y. H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17, s. 791 800. 9 Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). An Oncol, 2013, 24, s. 2278 2284. 10 Untch, M. Jackisch, C. H. Schneeweiss, A., at al.: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto GBG 69). Lancet Oncol, 2016, 17, s. 345 356. 11 Schneeweiss, A. Chia, S. Hickish, T., et al.: Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Lancet Oncol, 2016, 17, s. 791 800. 12 Swain, S. V. Ewer, M. S. Viale, G., et al.: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. An Oncol, 2018, 29, s. 646 653. 13 Baselga, J. Swain, S. M.: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 2009, 9, s. 463 475. 14 Gianni, L. Pienkowski, T. Im, Y.-H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s. 25 32. 15 Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013, 24, s. 2278 2284. 16 A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Earlystage Breast Cancer. NCT02132949. Dostupné z: https://clinicaltrials. gov/ct2/show/nct02132949, vyhledáno 9. 6. 2015, ClinicalTrials.gov Identifier: NCT02132949. Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny? prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň 1 Motzer, R. J. Tannir, N. M. McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. NEJM, 21. 3. 2018, dostupné z: NEJM.org. 2 Escudier, B. Sharma, P. McDermott, D. F., et al.: CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol, 2017, 72, s. 962 971, doi: 10.1016/j. eururo.2017.02.010, Epub 3. 3. 2017.

Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem kazuistika MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha 1 Heindrich, M. C. Maki, R. G. Corless, C. L., et al.: Sunitinib response in imatinib-esistant GIST correlates with KIT and PDGFR mutation status. J Clin Oncol, 2006, 24, s. 9502. 2 Demetri, G. D. van Oosterom, A. T., et al.: Efficacy and safety of sunitinib in patients with advanced gastointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, s. 6736 6746. Levá a pravá význam lokalizace primárního nádoru u kolorektálního karcinomu MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha 1 Hutchins, G. Southward, K. Handley, K., et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J ClinOncol, 2011, 29, s. 1261 1270. 2 Henrichsen-Schnack, T. Ladelund, S. Nilbert, M.: The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-egfr treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol, 2014, 53, s. 852 864. 3 Petrelli, F. Tomasello, G. Borgonovo, K., et al.: Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncology, 2017, 3, s. 211 219. 4 Dienstmann, R.: Tumor side as model of integrative molecular classification of colorectal cancer. Clin Cancer Res, 2018, 24, s. 989 990. 5 Shimada, Y. Kameyama, H. Nagahashi, M., et al.: Comprehensive genomic sequencing detectsim portant genetic differences between right-sided and left-sided colorectal cancer. Oncotarget, 2017, 8, s. 93567 93579. 6 Salem, M. E. Weinberg, B. A. Xiu, J., et al.: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, s. 86356 86368. 7 Guinney, J. Dienstmann, R. Wang, X., et al.: The konsensus molecular subtypes of colorectal cancer. Nat Med, 2015, 21, s. 1350 1356. 8 Pugh, S. A. Shinkins, B. Fuller, A., et al.: Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postre currence survival: data from the FACTS randomized controlled trial. Ann Surg, 2016, 263, s. 1143 1147. 9 Arnold, D. Lueza, B. Douillard, J. Y., et al.: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Med Oncol, 2017, 28, s. 1713 1729. 10 Holch, J. W. Ricard, I. Stintzing, S., et al.: The relevance of primary tumour location in patients with metastatic colorectal cancer: a metaanalysis of first-line clinical trials. Eur J Cancer, 2017, 70, s. 87 98. 11 Tejpar, S. Stintzing, S. Ciardiello, F., et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol, 2017, 3, s. 194 201. 12 Hibberd, A. A. Lyra, A. Ouwehand, A. C., et al.: Intestinal microbiota altered in patients with colon cancer and modified by probiotic intervention. BMJ open Gastroenterol, 2017, 4, s. e000145. 13 Mima, K. Nishihara, R. Qian, Z. R., et al.: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut, 2016, 65, s. 1973 1980. 14 Lee, G. H. Malietzis, G. Askari, A., et al.: Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol, 2015, 41, s. 300 308. Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno 1 Falcone, A. Andre, T. Edeline, J., et al.: Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mcrc): Preliminary results from the phase 3b, international, open-label, early-access PRECONNECT study. Abstract O-013. Poster prezentován na ESMO 20 th World Congress on Gastrointestinal Cancer, 20. 23. 6. 2018, Barcelona, Španělsko. 2 Emura, T. Nakagawa, F. Fujioka, A., et al.: An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med, 2004, 13, s. 249 255. 3 Mayer, R. J. Van Cutsem, E. Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med, 2015, 372, s. 1909 1919. 4 Yoshino, T. Mizunama, N. Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol, 2012, 13, s. 993 1001. Teysuno v léčbě metastatického karcinomu žaludku MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno 1 Lordick, F. Lorenzen, S. Yamada, Y., et al.: Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer, 2014, 17, s. 213 225. 2 Bang, Y. J. Van Cutsem, E. Feyereislova, A., et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, s. 687 697. 3 Fuchs, C. S. Tomasek, J. Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 2014, 383, s. 31 39. 4 Wilke, H. Muro, K. Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15, s. 1224 1235. 5 Okines, A. F. C. McCloud, P. Kang, Y., et al.: Meta-analysis of the REAL-2 and ML17032 trials comparing capecitabine with 5-FU in advanced oesofago gastric cancer. An Oncol, 2008, 19, viii169, abstrakt 513PD. 6 Ajani, J. A. Rodriguez, W. Bodoky, G., et al.: Multicenter phase iii comparison of cisplatin/s-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS Trial. J Clin Oncol, 2010, 28, s. 1547 1553. 7 Nakamura, M. Yamada, Y. Muro, K., et al.: The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Future Oncol, 2015, 11, s. 1471 1478, doi: 10.2217/fon.15.59. Ramucirumab cílený zásah jaterních metastáz karcinomu gastroezofageální junkce kazuistika MUDr. Sabina Svobodová MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně MUDr. Adam Peštál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně 1 Wilke, H. Muro, K. Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patiens with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15, s. 1224 1235. 2 Fuchs, C. S. Tomasek, J. Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet Oncol, 2014, 383, s. 31 39. 3 Shitara, K., et al.: Effect of post-discontinuation therapy on survival in metastatic gastric-gastroesophageal junction adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. ASCO, Chicago, červen 2018, poster 4044. 4 Bang, Y. J. Van Cutsem, E. Feyereislova, A., et al.: Trastuzumab

in combination with chemotherapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, s. 687 697. 5 Staněk, L. Tesařová, P. Gúrlich, R., et al.: Molekulární onkologie v kazuistikách. Current Media, Praha, 2017. 6 Klener, P. Klener, P. jr.: Nová protinádorová léčiva a léčebné strategie v onkologii. Grada, 2010. 7 Kolektiv autorů: Klinická onkologie. 2017, 30, suppl. 3: Advances in immunotherapy. 8 NCCN Clinical Guidelines in Oncology verze 2.2018, dostupné z: www.nccn.org. 9 Modrá kniha České onkologické společnosti, 24. aktualizace, platnost od 1. 3. 2018. 10 Souhrn údajů o přípravku Cyramza (ramucirumab ), Eli Lilly 1/2016, dostupné z: www.ema.europa.eu. Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem? MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 1 De Coana, Y. P. Wolodarski, M. Poschke, I., et al.: Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanom. Oncotarget, 2017, 8, s. 21539 21553. 2 Weber, J. S. Gibney, G. Sullivan, R. J., et al.: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol, 2016, 17, s. 943 955. 3 Hodi, F. S. Chesney, J. Pavlick, A. C., et al.: Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol, 2016, 17, s. 1558 1568. 4 Wolchok, J. D. Chiarion-Sileni, V. Gonzales, R., et al.: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med, 2017, 377, s. 1345 1356. 5 Menshawy, A. Eltonob, A. A. Barkat, S. A., et al.: Nivolumab monotherapy or in combination with ipilimumab for metastatic mela noma: systematic review and metaanalysis of randomized controlled trials. Melanoma Res, 27. 6. 2018, doi: 10.1097/CMR. 000000000000467, Epub před tiskem. 6 Long, G. V. Atkinson, V. Cebon, J. S., et al.: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol, 2017, 18, s. 1202 1210. 7 Retseck, J. Van der Weele, R. Lin, H. M., et al.: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immuno Therapy Cancer, 2016, 4, s. 38. 8 Chae, Y. K. Arya, A. Iams, W. J., et al.: Current landscape and future of dual anti-ctla4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and nonsmall cell lung cancer (NSCLC). J Immunother Cancer, 2018, 6, s. 39, doi: 10.1186/s40425-018-0349-3. 9 Schadendorf, D. Wolchok, J. D. Hodi, F. S., et al.: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol, 2017, 35, s. 3807 3814. 10 Long, G. V. Atkinson, V. Lo, S., et al.: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncology, 2018, 19, s. 672 681. 11 Hellmann, M. D. Callahan, M. K. Awad, M. M., et al.: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell, 2018, 33, s. 853 861. Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem kazuistika MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha 1 Long, G. V. Stroyakovskiy, D. Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibitional one in melanoma. N Engl J Med, 2014, 371, s. 1877 1888, doi: 10.1056/NEJMoa1406037. 2 Long, G. V. Flaherty, K. T. Stroyakovskiy, D., et al.: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 2017, 28, s. 1631 1639, doi: 10.1093/annonc/mdx176. 3 Ugurel, S. Röhmel, J. Ascierto, P. A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies update 2017. Eur J Cancer, 2017, 83, s. 247 257, doi: 10.1016/j. ejca.2017.06.028. Pacient s mnohočetným recidivujícím bazocelulárním karcinomem kazuistika MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec 1 Roš, T. Gajić, R. Rajić, N., et al.: Basal cell carcinoma: a frequent challenge. Serb J Dermatol Venerol, 2012, 4, s. 5 17. 2 Alter, M. Hillen, U. Leiter, U., et al.: Current diagnosis and treatment of basal cell carcinoma. CME-Article JDDG, 2015, s. 863 875. 3 Basset-Sequin, N. Hauschield, A. Kuntsfeld, R., et al.: Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open label trial. Eur J Cancer, 2017, 86, s. 334 348. 4 Alfieri, S. Bergamini, C. Granata, R., et al.: Retreatment with vismodegib after progression in advanced basal cell carcinoma: firsttime report of a single-institution experience. Target Oncol, 2018, 13, s. 253 256. 5 Sekulic, A. Migden, M. R. Oro, A. E., et al.: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New Eng J Med, 2012, s. 2171 2179. 6 Xie, J. Bartels, M. C. Barton, W. S.: Hedgehog signaling in human cancer. Onco Targets Ther, 2013, 6, s. 1425 1435. Lenvatinib nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc 1 Vlček, P.: Diferencovaný karcinom štítné žlázy nový pohled na jeho léčbu. Onkologie, 2011, 5. 2 Němec, J. Bílek, R. Zamrazil, V. Dvořák, J. Racek, P. Vlček, P.: The prognostic value of plasma Thyroglobulin at the time of hypothyroidism in the differentiated thyroid cancer. Nukl Med, 1995, 34, A179. 3 Tuttle, R. M., et al.: Novel concepts for initiating multitargeted kinase inhibitors in radioactiveiodine refractory differentiated toroid cancer. Best Prac Res Clin Endocrinol Metab, 2017, 31, s. 295 305. 4 Brose, S. M., et al.: Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol, 2017, 1 8. 5 Schlumberger, M., et al.: Lenvatinib versus placebo in radioiodine refractory thyroid cancer. New Eng J Med, 2015, 372, s. 621 630. 6 NCCN guidelines: Thyreoid Cancer, Ver. 1.2018. Dostupné z: https:// www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf, vyhledáno 20. 9. 2018. Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy? MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha 1 Drucker, B. J. Guilhot, F. O Brien, S. G., et al.: Five-year follow-up patiens receiving imatinib for chronic myeloid leukemia. N Engl J Med, 00, s. 2408 2417. 2 Hehlmann, R. Hochhaus, A. Baccarani, M., et al.; On behalf of the European Leukemia Net: Chronic myeloid leukemia. Lancet, 2007, 370, s. 342 350. 3 Huang, X. Cortes, J. Kantarjian, H.: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor. Cancer, 2012, 118, s. 3121 3127. 4 Baccarani, M. Deininger, M. W. Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, s. 872 884. 5 Mayer, J., ed., et al.: Léčebné postupy v hematologii: doporučení České hematologické společnosti ČLS JEP. Praha, Česká hematologická společnost České lékařské společnosti J. E. Purkyně, 2016. 6 Rousselot, P. Hughuet, F. Rea, D., et al.: Imatinib mesylate discontinuation on patients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood, 2007, 109, s. 68 70. 7 Mahon, F. X. Read, D. Guillhot, J., et al.: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at last 2 years: the prospective Stop Imatinib (STIM) trial. Lancet Oncol, 2010, 11, s. 1029 1035. 8 Etienne, G. Read, D. Guilhot, J., et al.: Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol, 2017, 35, s. 298. 9 Read, D. Nicolini, F. E. Tulliez, M., et al.: Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the

STOP 2G-TKI study. Blood, 2017, 129, s. 846 854. 10 Saussele, S. Richter, J. Hochhaus, A., et al.: The concept of treatment-free remission in chronic myeloid leukemia. Leukemia, 2016, 30, s. 1638 1647. 11 Saussele, S. Richter, J. Guilhot, J., et al.: First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. Haematologicy, 2014, 99, s. 792. 12 Mahon, X. F., et al.: Iterim analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in CML: The EURO-SKI study. Blood, 2014, 124, abstrakt 151. 13 Jabbour, E. Kantarjian, H.: Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol, 2018, 93, s. 442 459. 14 Saussele, S. Richter, J. Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapyin chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol, 2018, 19, s. 747 757. 15 Clark, C. E. Polydoros, F. Apperley, J. F., et al.: De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an iterim analysis of a non-randomised, phase 2 trial. Lancet Haematol, 2017, s. 310 316. 16 Russo, D. Martinelli, G. Malagola, M., et al.: Effect and outcome of policy intermittent treatment imatinib in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, s. 5138 5144. 17 Ambruzzese, E. Trawinska, M. M. Fabritti, S. M., et al.: Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol, 2016, 9, s. 781 791. 18 Holyoake, L. Vetrie, D.: The chronic myeloid leukemia stem cell: stemming the tide or persistence. Blood, 2017, 129, s. 1595 1606. 19 Hjorth-Hansen, H. Stentoft, J. Richter, J., et al.: Safety and efficacy of the combination of pegylated-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia, 2016, 30, s. 1853 1860. Hodgkinův lymfom u starších nemocných MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha 1 Hlavní stránka ÚZIS ČR. Dostupné z: http://www.uzis.cz/links/weblink, vyhledáno 29. 6. 2018. 2 Stark, G. L., et al.: Hodgkin s disease in the elderly: a population-based study. Br J Haematol, 2002, 119, s. 432 440. 3 Erdkamp, F. L. Breed, W. P. Bosch, L. J., et al.: Hodgkin disease in the elderly. A registry-based analysis. Cancer, 1992, 70, s. 830 834. 4 Levis, A., et al.: Probability of cure in elderly Hodgkin s disease patients. Haematologica, 1994, 79, s. 46 54. 5 Mir, R., et al.: Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer, 1993, 71, s. 1857 1866. 6 Roy, P. Vaughan Hudson, G. Vaughan Hudson, B., et al.: Longterm survival in Hodgkin s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer, 2000, 36, s. 384 389. 7 Pulte, D., et al.: Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol, 2014, 164, s. 851 857. 8 Evens, A. M., et al.: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood, 2012, 119, s. 692 695. 9 Stamatoullas, A., et al.: Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol, 2015, 170, s. 179 184. 10 Enblad, G. Gustavsson, A. Sundström, C., et al.; Swedish Lymphoma Study Group: Patients above sixty years of age with Hodgkin s lymphoma treated with a new strategy. Acta Oncol, 2002, 41, s. 659 667. 11 van Spronsen, D. J. Janssen-Heijnen, M. L. Breed, W. P., et al.: Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin s disease and non-hodgkin s lymphoma, 1993 1996. Ann Hematol, 1999, 78, s. 315 319. 12 Thyss, A. Saada, E. Gastaud, L., et al.: Hodgkin s lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis, 2014, 6, e2014050. 13 Guinee, V. F., et al.: The prognosis of Hodgkin s disease in older adults. J Clin Oncol, 1991, 9, s. 947 953. 14 Kim, H. K. Silver, B. Li, S., et al.: Hodgkin s disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys, 2003, 56, s. 556 560. 15 Specht, L. Nissen, N. I.: Hodgkin s disease and age. Eur J Haematol, 1989, 43, s. 127 135. 16 Engert, A., et al.: Hodgkin s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin s Study Group. J Clin Oncol, 2005, 23, s. 5052 5060. 17 Landgren, O., et al.: Hodgkin s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica, 2003, 88, s. 438 444. 18 Ballova, V., et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin s disease comparing BEACOPP baseline and COPP- ABVD (study HD9elderly). Ann Oncol, 2005, 16, s. 124 131. 19 Hasenclever, D. Diehl, V.: A prognostic score for advanced Hodgkin s disease. International Prognostic Factors Project on Advanced Hodgkin s Disease. N Engl J Med, 1998, 339, s. 1506 1514. 20 Cuccaro, A., et al.: Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis, 2014, 6. 21 Jagadeesh, D. Diefenbach, C. Evens, A. M.: XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol, 2013, 31, suppl. 1, s. 69 75. 22 Enblad, G. Glimelius, B. Sundström, C.: Treatment outcome in Hodgkin s disease in patients above the age of 60: a population-based study. Ann Oncol, 1991, 2, s. 297 302. 23 Wedelin, C., et al.: Prognostic factors in Hodgkin s disease with special reference to age. Cancer, 1984, 53, s. 1202 1208. 24 Walker, A., et al.: Survival of the older patient compared with the younger patient with Hodgkin s disease. Influence of histologic type, staging, and treatment. Cancer, 1990, 65, s. 1635 1640. 25 Levis, A., et al.: VEPEMB in elderly Hodgkin s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol, 2004, 15, s. 123 128. 26 Armstrong, A. A., et al.: Epstein-Barr virus and Hodgkin s disease: further evidence for the three disease hypothesis. Leukemia, 1998, 12, s. 1272 1276. 27 Klimm, B. Diehl, V. Engert, A.: Hodgkin s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park, N.Y.), 2007, 21, s. 982 990; diksuze 990, 996, 998 passim. 28 Greaves, P., et al.: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol, 2013, 31, s. 256 262. 29 Kelley, T. W. Pohlman, B. Elson, P., et al.: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol, 2007, 128, s. 958 965. 30 Sieber, M. Engert, A. Diehl, V.: Treatment of Hodgkin s disease: results and current concepts of the German Hodgkin s Lymphoma Study Group. Ann Oncol, 2000, 11, suppl. 1, s. 81 85. 31 Wildiers, H., et al.: International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol, 2014, 32, s. 2595 2603. 32 Hurria, A., et al.: Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol, 2011, 29, s. 1290 1296. 33 Puts, M. T. E., et al.: An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol, 2014, 25, s. 307 315. 34 Böll, B., et al.: ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol, 2013, 31, s. 1522 1529. 35 Böll, B., et al.: Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol, 2013, 31, s. 4431 4437. 36 Evens, A. M., et al.: The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol, 2013, 161, s. 76 86. 37 Böll, B., et al.: Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 2016, 127, s. 2189 2192. 38 Zallio, F., et al.: Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol, 2016, 172, s. 879 888. 39 Proctor, S. J., et al.: Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood, 2012, 119, s. 6005 6015. 40 Halbsguth, T. V., et al.: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood, 2010, 116, s. 2026 2032. 41 Engert, A., et al.: Reduced treatment intensity in patients with earlystage Hodgkin s lymphoma. N Engl J Med, 2010, 363, s. 640 652. 42 Behringer, K., et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, 2015, 385, s. 1418 1427. 43 Radford, J., et al.: Results of a trial of PET-directed therapy for earlystage Hodgkin s lymphoma. N Engl J Med, 2015, 372, s. 1598 1607. 44 Raemaekers, J. M. M., et al.: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 2014, 32, s. 1188 1194. 45 Specht, L., et al.: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys, 2014, 89, s. 854 862. 46 Longo, D. L., et al.: Twenty years of MOPP therapy for Hodgkin s disease. J Clin Oncol, 1986, 4, s. 1295 1306. 47 Bonadonna, G. Valagussa, P. Santoro, A.: Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin s disease. A report of 8-year results. Ann Intern Med, 1986, 104, s. 739 746. 48 Duggan, D. B., et al.: Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin s disease: report of an intergroup trial. J Clin Oncol, 2003, 21, s. 607 614. 49 Bartlett, N. L. Rosenberg, S. A. Hoppe, R. T., et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advancedstage Hodgkin s disease: a preliminary report. J Clin Oncol, 1995, 13, s. 1080 1088. 50 Hoskin, P. J., et al.: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol, 2009, 27, s. 5390 5396. 51 Weekes, C. D., et al.: Hodgkin s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol, 2002, 20, s. 1087 1093. 52 Macpherson, N., et al.: Treatment of elderly Hodgkin s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma, 2002, 43, s. 1395 1402. 53 Kolstad, A., et al.: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin s lymphoma. Leuk Lymphoma, 2007, 48, s. 570 576. 54 Johnson, P., et al.: Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin s lymphoma. N Engl J Med, 2016, 374, s. 2419 2429. 55 Younes, A., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin s lymphoma. J Clin Oncol, 2012, 30, s. 2183 2189. 56 Younes, A., et al.: Brentuximab vedotin (SGN-35) for relapsed CD30- positive lymphomas. N Engl J Med, 2010, 363, s. 1812 1821. 57 Chen, R., et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol, 2017, 35, s. 2125 2132. 58 Ansell, S. M.: Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res, 2017, 23, s. 1623 1626. 59 Gopal, A. K., et al.: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma, 2014, 55, 2328 2334. 60 Forero-Torres, A., et al.: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood, 2015, 126, s. 2798 2804. 61 Friedberg, J. W., et al.: Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged 60 years with HL. Blood, 2017, doi:10.1182/blood-2017-06-787200. 62 Connors, J. M., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin s lymphoma. N Engl J Med, 2018, 378, s. 331 344. 63 Evens, A. M., et al.: Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical Hodgkin lymphoma (chl): Final results from a multicenter phase II study. Blood, 2017, 130, s. 733. 64 Younes, A., et al.: Nivolumab for classical Hodgkin s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol, 2016, 17, s. 1283 1294. 65 Armand, P., et al.: Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol, 2018, 36, s. 1428 1439. 66 Armand, P., et al.: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab